Biswas, A., Loeffler, K., Kim, D. et al. Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses. npj Vaccines 10, 225 (2025)
Influenza is a global health concern, causing over 300,000 deaths worldwide annually. Current vaccines and natural infection mainly elicit antibodies against the variable head domain of the hemagglutinin (HA) glycoprotein. While these antibodies are highly neutralizing, the head domain constantly mutates due to selective pressure, causing the immune response to be strain-specific. Targeting the conserved HA stalk domain, however, has been shown to be a promising approach for a broadly protective vaccine. We previously demonstrated that presenting HA in an inverted orientation on virus-like particles (VLPs) significantly enhanced the induction of stalk-directed, cross-reactive antibodies compared to HA presented in a regular orientation. Here, we evaluated the protective efficacy of the inverted HA vaccine (VLP-HAinv) in mice against homologous, heterologous, and heterosubtypic influenza A virus challenges. VLP-HAinv vaccination in mice provided complete protection against homologous and heterologous H1N1 challenges as well as partial protection against a heterosubtypic challenge with bovine H5N1.
See Also:
Latest articles in those days:
- High-throughput pseudovirus neutralisation maps the antigenic landscape of influenza A/H1N1 viruses 5 hours ago
- Timely vaccine strain selection and genomic surveillance improve evolutionary forecast accuracy of seasonal influenza A/H3N2 5 hours ago
- Evaluation of a Novel Data Source for National Influenza Surveillance: Influenza Hospitalization Data in the National Healthcare Safety Network, United States, September 2021-April 2024 5 hours ago
- Scenarios for pre-pandemic zoonotic influenza preparedness and response 5 hours ago
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk 1 days ago
[Go Top] [Close Window]


